Expression of leucine-rich repeats and immunoglobulin-like domains (LRIG) proteins in human ependymoma relates to tumor location, WHO Grade, and patient age

Clinical Neuropathology

Volumn 28, Issue 1, 2009, Pages 21-27

  Yi, W ^a   Haapasalo, H ^b   Holmlund, C ^a   Jarvela S ^b   Raheem, O ^b   Bergenhelim, A T ^a   Hedman, Håkan ^a   Henriksson, Roger ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Ependymoma; LRIG; Subcellular localization; TMA; WHO Grade

Indexed keywords

LEUCINE RICH REPEATS AND IMMUNOGLOBULIN LIKE DOMAIN PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; LRIG1 PROTEIN, HUMAN; LRIG3 PROTEIN, HUMAN; MEMBRANE PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CARCINOGENESIS; CELLULAR DISTRIBUTION; CHILD; CLINICAL ARTICLE; CYTOPLASM; DISEASE ASSOCIATION; EPENDYMOMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFANT; MALE; NEUROSURGERY; POSTERIOR FOSSA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR LOCALIZATION; AGE; BIOSYNTHESIS; BRAIN TUMOR; CELL NUCLEUS; GENE EXPRESSION; METABOLISM; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; SPINAL CORD TUMOR; TISSUE MICROARRAY; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BRAIN NEOPLASMS; CELL NUCLEUS; CHILD; CHILD, PRESCHOOL; CYTOPLASM; EPENDYMOMA; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MIDDLE AGED; SPINAL NEOPLASMS; TISSUE ARRAY ANALYSIS; WORLD HEALTH ORGANIZATION;

EID: 62849109375     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.5414/NPP28021     Document Type: Article

References (31)

1. Gilbertson RJ, Bentley L, Hernan R, Junttila TT, Frank AJ, Haapasalo H, Connelly M, Wetmore C, Curran T, Elenius K, Ellison DW. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res. 2002; 8: 3054-3064.
2. Gonzales M. The 2000 World Health Organization classification of tumors of the nervous system. J Clin Neurosci. 2001; 8: 1-3.
3. Gudinaviciene I, Pranys D, Juozaityte E. Impact of morphology and biology on the prognosis of patients with gliomas. Medicina (Kaunas). 2004; 40: 112-120.
4. Guo D, Holmlund C, Henriksson R, Hedman H. The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. Genomics. 2004; 84: 157-165.
5. Guo D, Nilsson J, Haapasalo H, Raheem O, Bergenheim T, Hedman H, Henriksson R. Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1- -3) as prognostic indicators in astrocytic tumors. Acta Neuropathol (Berl). 2006; 111: 238-246.
6. Gur G, RubinC, Katz M, Amit I, Citri A, Nilsson J, Amariglio N, Henriksson R, Rechavi G, Hedman H, Wides R, Yarden Y. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation.EMBO J. 2004; 23: 3270-3281.
7. Hedman H, Henriksson R. LRIG inhibitors of growth factor signalling - double-edged swords in human cancer? Eur J Cancer. 2007; 43: 676-682.
8. Hedman H, Nilsson J, Guo D, Henriksson R. Is LRIG1 a tumor suppressor gene at chromosome 3p14.3? Acta Oncol. 2002; 41: 352-354.
9. Holmlund C, Nilsson J, Guo D, Starefeldt A, Golovleva I, Henriksson R, Hedman H. Characterization and tissue-specific expression of human LRIG2. Gene. 2004; 332: 35-43.
10. Jarvela S, Nordfors K, Jansson M, Haapasalo J, Paljarvi L, Kalimo H, Kinnula V, Soini Y, Haapasalo H. Antioxidant enzymes in ependymal brain tumors: the role of thioredoxin as a prognosis factor. In press.
11. Jeuken JW, Sprenger SH, Gilhuis J, Teepen HL, Grotenhuis AJ, Wesseling P. Correlation between localization, age, and chromosomal imbalances in ependymal tumors as detected by CGH. J Pathol. 2002; 197: 238-244.
12. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumors. Brain Pathol. 1993; 3: 255-268.
13. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002; 61: 215-229.
14. Korshunov A, Golanov A, Sycheva R, Timirgaz V. The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: an analysis of 258 patients. Cancer. 2004; 100: 1230-1237.
15. Korshunov A, Neben K, Wrobel G, Tews B, Benner A, Hahn M, Golanov A, Lichter P. Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. Am J Pathol. 2003; 163: 1721-1727.
16. Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, Carraway KL 3rd, Sweeney C. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem. 2004; 279: 47050-47056.
17. Ledda F, Bieraugel O, fard SS, Vilar M, Paratcha G. Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF. J Neurosci. 2008; 28: 39-49.
18. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol. 2007; 114: 97-109.
19. Mendrzyk F, Korshunov A, Benner A, Toedt G, Pfister S, Radlwimmer B, Lichter P. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma.Clin Cancer Res. 2006; 12: 2070-2079.
20. Moynihan TJ. Ependymal tumors. Curr Treat Options Oncol. 2003; 4: 517-523.
21. Nilsson J, Starefeldt A, Henriksson R, Hedman H. LRIG1 protein in human cells and tissues. Cell Tissue Res. 2003; 312: 65-71.
22. Nilsson J, Vallbo C, Guo D, Golovleva I, Hallberg B, Henriksson R, Hedman H. Cloning, characterization, and expression of human LIG1. Biochem Biophys Res Commun. 2001; 284: 1155-1161.
23. Packer RJ. New insights into childhood ependymomas. Curr Neurol Neurosci Rep. 2005; 5: 107-109.
24. Poppleton H, Gilbertson RJ. Stem cells of ependymoma. Br J Cancer. 2007; 96: 6-10.
25. Reni M, Brandes AA, Vavassori V, Cavallo G, Casagrande F, Vastola F, Magli A, Franzin A, Basso U, Villa E. A multicenter study of the prognosis and treatment of adult brain ependymal tumors. Cancer. 2004; 100: 1221-1229.
26. Schiffer D. Brain tumors. Biology, pathology, and clinical references Berlin: Springer; 2nd ed. 1997.
27. Schiffer D, Giordana MT. Prognosis of ependymoma. Childs Nerv Syst. 1998; 14: 357-361.
28. Shattuck DL, Miller JK, Laederich M, Funes M, Petersen H, Carraway KL 3rd, Sweeney C. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol. 2007; 27: 1934-1946.
29. Tihan T, Zhou T, Holmes E, Burger PC, Ozusyal S, Rushing EJ. The prognostic value of histological grading of posterior fossa ependymomas in children: a Children's Oncology Group study and a review of prognostic factors. Mod Pathol. 2008; 21: 165-177.
30. Yang WM, Yan ZJ, Ye ZQ, Guo DS. LRIG1, a candidate tumor suppressor gene in human bladder cancer cell line BIU87. BJU Int. 2006; 98: 898-902.
31. Yi W, Ye F, Guo D, Xue D, Lei T. Expression and significance of LRIG1 gene in human astrocytomas. Chinese-German J Clin Oncol. 2005; 4: 225-228.